--- title: "Weekly Recap | 10X Genomics -13.74%, CEO sale meets overvaluation warning" type: "News" locale: "en" url: "https://longbridge.com/en/news/301472918.md" description: "10X Genomics (TXG) closed the week at $80.65, down 13.74%. The S&P 500 gained 1.15%, leaving the stock roughly 14.89 percentage points behind the benchmark. The daily bars show an up-and-down path: Monday (Oct 5) firmed to $97.74, Tuesday (Oct 6) spiked to a high of $102.81 before sliding to $80.66, Wednesday (Oct 7) fell further to $76.10, Thursday (Oct 8) bottomed around $70.94 and settled at $77.28, and Friday (Oct 9) recovered to $80.65. The stock swung 34." datetime: "2026-10-10T07:57:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/301472918.md) - [en](https://longbridge.com/en/news/301472918.md) - [zh-HK](https://longbridge.com/zh-HK/news/301472918.md) generator: "portal-rs" --- # Weekly Recap | 10X Genomics -13.74%, CEO sale meets overvaluation warning ## The Week 10X Genomics (TXG) closed the week at $80.65, down 13.74%. The S&P 500 gained 1.15%, leaving the stock roughly 14.89 percentage points behind the benchmark. The daily bars show an up-and-down path: Monday (Oct 5) firmed to $97.74, Tuesday (Oct 6) spiked to a high of $102.81 before sliding to $80.66, Wednesday (Oct 7) fell further to $76.10, Thursday (Oct 8) bottomed around $70.94 and settled at $77.28, and Friday (Oct 9) recovered to $80.65. The stock swung 34.09% from low to high, a bumpy week marked by a sharp pull-back after an early rally. ## Key Events The week mixed new research deals with insider-selling pressure. On Oct 7, 10x Genomics announced a collaboration to advance single-cell and spatial applications across solid tumours and blood cancers; a day later it detailed a partnership with Fred Hutchinson Cancer Center for cancer technologies. At the same time, the CEO’s share reduction and SimplyWall’s overvaluation warning coincided with the sharpest moves: the stock first rose more than 9%, then fell more than 13% within the same session on Tuesday. Sector-wise, several life-science names hit 52-week highs, but TXG’s own sell-off kept it out of that momentum. ## Analyst Ratings Nineteen analysts cover TXG: 6 rate it buy, 1 overweight, 12 hold, and none recommend underweight or sell. The consensus rating is buy, while the consensus target of $69.47 sits about 13.87% below the current price of $80.65. The target range is wide, from a high of $110.00 to a low of $40.00, pointing to split views on valuation. Within the life-science tools and services industry, TXG ranks 9th out of 54 companies. ## The Week Ahead Macro data leads the calendar. On Oct 14, the US reports CPI and core CPI: core CPI is expected at 2.5% year-on-year from 2.4%, and headline CPI at 3.7% from 3.4%, with month-on-month figures due the same day. The prints could weigh on rate-sensitive tech and biotech valuations. Earlier in the week, Oct 13 brings NFIB small-business optimism and existing-home sales data. On the company side, the next test is whether the new partnerships translate into firmer guidance or commercial traction, and whether valuation concerns ease. ## In Short The pull-back landed mostly between Tuesday and Thursday, alongside the CEO’s share sale and a high-valuation warning, while new cancer-research collaborations failed to lift the tape. Analyst positioning is cautious rather than aggressive: 12 holds against 6 buys and 1 overweight, and the consensus target sits below spot. Valuation shows a PB near 12.73x with negative earnings, so profit momentum is still missing. The latest session also showed large-lot money leaning defensively. What comes next hinges on whether core CPI stays sticky, and whether the collaboration news gets followed by concrete product or revenue signals. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [TXG.US](https://longbridge.com/en/quote/TXG.US.md) ## Related News & Research - [10x Genomics (TXG) Expands Fred Hutch Cancer Work, Is The Valuation Case Still Convincing?](https://longbridge.com/en/news/302193585.md) - [J.P. Morgan Reaffirms Their Hold Rating on 10x Genomics (TXG)](https://longbridge.com/en/news/302183593.md) - [10x Genomics and Fred Hutch partner on cancer technologies](https://longbridge.com/en/news/301250716.md) - [Meta Stock Forecast: META Defends $694 Support as a $10 Billion Legal Charge and Capex Test Loom](https://longbridge.com/en/news/302380893.md) - [Nvidia Reportedly Just Landed $35 Billion In Chip Orders From Chinese Companies. Here's Why That Could Be Great News for the Stock](https://longbridge.com/en/news/302459774.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**